SUPPLEMENTARY FIGURES



Supplementary Figure 1. Validate the expression of the core genes in the UC and OA cohorts. (A) Differential expression analysis of 5 core genes in the UC cohort. (B) Differential expression analysis of 5 core genes in the OA cohort. Abbreviations: UC: ulcerative colitis; OA: osteoarthritis; ns: no significance. *P < 0.05 **P < 0.01.



Supplementary Figure 2. Functional annotation of core genes in the biomarker panel based on consensus clustering in RA. (A) Consensus score matrix of all samples when the number of clusters k = 2. (B) CDF curves of the consistency matrix for each k-value. (C) Differential analysis of the five core genes in the two subtypes (cluster 1 and cluster 2) obtained by consensus clustering. (D) Unsupervised PCA plots of samples in two new groups (high-risk and low-risk). (E) Volcanoes of differentially expressed genes in high-risk and low-risk group. (F) Gene ontology biological process and (G) KEGG enrichment analysis of DEGs between high-risk and low-risk. GSEA analysis of (H) Immune Response, and (I) Rheumatoid Arthritis signaling pathways. Abbreviations: CDF: cumulative distribution function; PCA: Principal Component Analysis; KEGG: Kyoto Encyclopedia of Genes and Genomes; DEG: Differentially Expressed Gene; GSEA: Gene Set Enrichment Analysis; TNF: tumor necrosis factor. **P < 0.01, ****P < 0.0001.





Supplementary Figure 3. Differential analysis of immune cell type scores based on CIBERSORT. *P < 0.05; ****P < 0.0001.



Supplementary Figure 4. Immuno-infiltration analysis of core genes in RA. (A) Heat map of immune cell type scores based on ssGSEA. (B) Differential analysis of the sum of immune scores based on ssGSEA. (C) Differential analysis of immune cell type scores based on ssGSEA. (D) Differential analysis of ESTIMATE-based immune scores and ESTIMATE score. (E) Differential analysis of immune cell type scores based on cIBERSORT. Abbreviation: ssGSEA: single sample Gene Set Enrichment Analysis. *P < 0.05; **P < 0.01; ***P < 0.001; ***P < 0.001.



Supplementary Figure 5. Verification of the diagnostic value of the biomarker panel in RA validation cohorts. (A) Expression analysis and (B) ROC curve analysis of core genes in GSE77298. Abbreviations: ROC: Receiver Operating Characteristic; AUC: Area Under Curve; ns: no significance. *P < 0.05; **P < 0.01; ***P < 0.001.



Supplementary Figure 6. Construction of miRNA-mRNA co-expression network. (A) Acquisition of core gene co-expression miRNA Venn diagrams based on TargetScan, miRWalk, and miRDB. (B) Visualization of co-expression networks of miRNAs and core genes.



Supplementary Figure 7. Validation of biomarker panel expression by q-PCR in serum samples from patients with RA and healthy controls. Differential comparison of mRNA expression levels of CXCL10 (A), CXCL9 (B), SPP1 (C), AQP9 (D), MT1M (E) in serum samples from patients with RA and healthy controls. *P < 0.05; **P < 0.01; ***P < 0.001.